Drug Profile
AbGn 7
Alternative Names: AbGn-7Latest Information Update: 06 Jul 2020
Price :
$50
*
At a glance
- Originator AbGenomics Corporation
- Developer AltruBio
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastric cancer; Solid tumours
Most Recent Events
- 31 Jan 2013 AbGenomics completes a phase Ia/b trial in Solid tumours (late-stage disease, second-line therapy or greater) including Gastric cancer (combination therapy, late-stage disease) in USA and Taiwan (NCT01466569)
- 04 Jun 2012 Phase-I clinical trials in Gastric cancer (combination therapy, late-stage disease) in Taiwan (IV)
- 04 Jun 2012 Phase-I clinical trials in Solid tumours (combination therapy, late-stage disease) in Taiwan (IV)